Safety and Efficacy of Programmed Cell Death 1 and Programmed Death Ligand-1 Inhibitors in the Treatment of Cancer: An Overview of Systematic Reviews

BACKGROUND: An influx of systematic reviews (SRs) of programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) checkpoint inhibitors in cancer treatment with or without meta-analysis and with different methodological quality and inconsistent results have been published, confusing clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Shun-Long, Luo, Jing, Wei, Hua, Qin, Xiao-Li, Du, Su-Ya, Wang, Song, Jiang, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326177/
https://www.ncbi.nlm.nih.gov/pubmed/35911744
http://dx.doi.org/10.3389/fimmu.2022.953761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326177/
https://www.ncbi.nlm.nih.gov/pubmed/35911744
http://dx.doi.org/10.3389/fimmu.2022.953761

Ejemplares similares